Navigation Links
Biomarker identified in relation to drug response in refractory urothelial cancer
Date:3/31/2012

CHICAGO The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.

"Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea Necchi, M.D., faculty member in the department of medicine at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. "Patients who fail to be cured after multiple chemotherapy regimens have a poor survival estimate, and palliative care is a reasonable trade-off."

Data from the phase II proof-of-concept trial identified pazopanib as the first targeted compound to have clinically meaningful activity in patients with refractory urothelial cancer, according to Necchi.

"Our data indicate that pazopanib seems to be a legitimate drug in this disease," said Necchi. "Most interestingly, our biomarker analysis clearly pointed out the role of rising levels of circulating interleukin-8 as an early and potentially practice-changing indicator of tumor resistance and poor survival."

The researchers assigned 41 patients with relapsing or progressing urothelial cancer between 2010 and 2011 to 800 mg once-daily pazopanib. All patients had at least one prior chemotherapy regimen for metastatic disease.

At follow-up, seven patients had a partial response to therapy and 24 patients had stable disease an overall clinical benefit of 76 percent. Median progression-free survival was 2.6 months, and median overall survival was 4.7 months. However, 10 percent of patients had a long-term cure after a median follow-up of 19 months.

The researchers examined blood samples for predictive biomarkers at baseline and every four weeks. They found that early rising levels of interleukin-8 (e.g., after four weeks of pazopanib) were associated with tumor progression and shorter overall survival.

"This trial gave a clear proof of concept that will require confirmation on a larger number of patients," Necchi said. "However, the preliminary findings, mainly regarding the role of interleukin-8 levels, have the potential to change at least the concept of new trial design with antiangiogenic agents in this disease."

Necchi served as an adviser and consultant for GlaxoSmithKline Inc. The current study was sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori. GlaxoSmithKline Inc. provided the drug supply and granted independent radiologic review, which was performed at Columbia University Medical Center.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Panel of serum biomarkers may reduce number of lung biopsies needed
2. Biomarkers identify acute kidney injury in emergency patients
3. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
4. Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
5. Mass. General Cancer Center and Vall dHebron Institute of Oncology biomarker alliance
6. Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease
7. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
8. Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio
9. FDA clears biomarker test for ovarian cancer
10. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
11. Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
(Date:12/8/2016)... Wichita, KS (PRWEB) , ... December 08, 2016 ... ... and financial consultation services to families and business owners in and around central ... to provide assistance to at-risk youth in the region. , Headquartered in Wichita, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... MA (PRWEB) , ... December 07, 2016 , ... They ... They are sisters and wives, brothers and fathers, from New England and around the ... and its stigma, and are brought together in a beautiful and compelling new photographic ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016 Hoovers Research analysis ... using the combinational analytical tools. The report contains ... research sources to present unique and reliable analysis. ... the market during the next five years, including ... comprises of sub markets, regional and country level ...
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... , Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and ... infusion services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, ... "As we continue to build on ...
Breaking Medicine Technology: